Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome

Influenza Vaccine Clinical Trial

Official title:

Cost-consequence Analysis of Influenza Vaccination Among the Staff of a Large Teaching Hospital in Rome, Italy: A Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06304038
• Other study ID #: 2018
• Status: Completed
• Start date: October 16, 2017
• Est. completion date: November 14, 2019

Study information

• Verified date: March 2024
• Source: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Flu vaccination, as well as being effective to prevent seasonal influenza, decreases staff illness and absenteeism and reduces costs resulting from loss of productivity. Despite the effectiveness of flu vaccination, the seasonal coverage among healthcare workers is usually low. The aim of this retrospective observational study is to analyze the vaccination coverage rate among all employees (healthcare workers and administrative staff) of a large teaching hospital in Rome during the 2017-2018 influenza season, to perform a cost-consequence analysis of influenza vaccination (by evaluating the absenteeism due to illness in the epidemic period), and to assess the impact of vaccination in terms of both costs and sick days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5483
• Est. completion date: November 14, 2019
• Est. primary completion date: April 29, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Healthcare workers at Fondazione Policlinico Universitario "A.Gemelli" IRCCS

Exclusion Criteria:

• Healthcare workers not working at Fondazione Policlinico Universitario "A.Gemelli" IRCCS

Related Conditions & MeSH terms

• Cost-Benefit Analysis
• Influenza Vaccine
• Influenza, Human

Intervention

Drug:
• Flu Vaccine
Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra

Locations

Country	Name	City	State
Italy	Fondazione Policlinico Universitario "A.Gemelli" IRCCS	Rome

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness of the quadrivalent vaccine	Effectiveness of the quadrivalent vaccine in reducing the number of working days lost due to influenza syndrome	33 weeks
Primary	Economic impact of the quadrivalent vaccine	Economic impact (for the company and society) of vaccination as part of a vaccination campaign on the healthcare workers of the teaching hospital.	33 weeks
Secondary	Expected economic savings for each one percentage point increase in vaccination coverage	Expected economic savings for each one percentage point increase in coverage on the health personnel of the teaching hospital	33 weeks
Secondary	Non-economic incentives for healthcare personnel who decide to vaccinate	Non-economic incentives for healthcare personnel who decide to vaccinate, in view of the financial savings for the company, linked to increased vaccination coverage	33 weeks